Certara Products - Phoenix Archives | Page 5 of 6

Case Study

How A Biotech Startup Company Increased Flexibility and Efficiency by Switching to Phoenix Hosted

Discover how a biotech startup enhanced flexibility and efficiency by adopting Phoenix Hosted, streamlining workflows…

CertaraSeptember 8, 2023

Case Study

Leveraging Pharmacokinetic Modeling & Scientific Communications Expertise Advances Sarcoidosis Drug Program

Certara's support, from dose optimization to medical writing, helps pharmaceutical companies advance their research, make…

CertaraJune 1, 2023

Conference

American College of Toxicology 2025 Annual Meeting

– – Booth

CertaraMay 24, 2023

Blog

Application of PK/PD Modeling and Simulation in Drug Discovery and Development in China

By Yuancheng Chen, Research Associate of Phase 1 Unit, Huashan Hospital, Fudan University, and visiting…

CertaraAugust 7, 2020

Blog

Conventional & Mechanistic IVIVC: Complementary or Clashing Methods?

An IVIVC (in vitro-in vivo correlation) is a mathematical relationship that predicts key pharmacokinetic parameters…

CertaraFebruary 9, 2016

Blog

Common Misconceptions About Computer System Validation

Drug development professionals frequently use computer systems to help them understand the pharmacokinetics (PK) and…

CertaraJanuary 28, 2015

Blog

Using Modeling and Simulation to Quantify the PK of an Anti-HIV Drug for Babies

As a scientist at Certara and proud Dad to my three kids, pediatric drug development…

CertaraJanuary 15, 2015

Blog Knowledge Base

Understanding Steady State Pharmacokinetics

CertaraNovember 25, 2013

Blog Knowledge Base

Calculating Urine PK Parameters

Pharmacokinetic analysis normally focuses on systemic exposure to a drug; however, much can be learned…

CertaraDecember 6, 2012

Blog Knowledge Base

The Difference Between Vd and Vss

There are many terms used to represent volume of distribution, but two common ones are…

CertaraMarch 31, 2011

Certara Products – Phoenix

How A Biotech Startup Company Increased Flexibility and Efficiency by Switching to Phoenix Hosted

Leveraging Pharmacokinetic Modeling & Scientific Communications Expertise Advances Sarcoidosis Drug Program

American College of Toxicology 2025 Annual Meeting

Application of PK/PD Modeling and Simulation in Drug Discovery and Development in China

Conventional & Mechanistic IVIVC: Complementary or Clashing Methods?

Common Misconceptions About Computer System Validation

Using Modeling and Simulation to Quantify the PK of an Anti-HIV Drug for Babies

Understanding Steady State Pharmacokinetics

Calculating Urine PK Parameters

The Difference Between Vd and Vss

Newsletter sign up

Quick links

Solutions

Contact